0
Catégories
|
TABAC > sevrage tabagique > méthode de sevrage > méthode individuelle > approche pharmacologique > placebo
placebo |
Documents disponibles dans cette catégorie (5)
Ajouter le résultat dans votre panier Affiner la rechercheA comparison of sustained-release bupropion and placebo for smoking cessation / Richard D. Hurt (1997)
Titre : A comparison of sustained-release bupropion and placebo for smoking cessation Type de document : texte imprimé Auteurs : Richard D. Hurt, Auteur ; David P.L. Sachs, Auteur ; Elbert T. Glover, Auteur ; Kenneth P. Offord, Auteur Editeur : Massachusetts Medical Society Année de publication : 1997 Collection : New England Journal of Medicine num. 337:17 Importance : p. 1195-1202 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:placeboIndex. décimale : TA 6.2.3.2 Autres produits Résumé : BACKGROUND AND METHODS:
Trials of antidepressant medications for smoking cessation have had mixed results. We conducted a double-blind, placebo-controlled trial of a sustained-release form of bupropion for smoking cessation. We excluded smokers with current depression, but not those with a history of major depression. The 615 subjects were randomly assigned to receive placebo or bupropion at a dose of 100, 150, or 300 mg per day for seven weeks. The target quitting date (or "target quit date") was one week after the beginning of treatment. Brief counseling was provided at base line, weekly during treatment, and at 8, 12, 26, and 52 weeks. Self-reported abstinence was confirmed by a carbon monoxide concentration in expired air of 10 ppm or less.
RESULTS:
At the end of seven weeks of treatment, the rates of smoking cessation as confirmed by carbon monoxide measurements were 19.0 percent in the placebo group, 28.8 percent in the 100-mg group, 38.6 percent in the 150-mg group, and 44.2 percent in the 300-mg group (P<0.001). At one year the respective rates were 12.4 percent, 19.6 percent, 22.9 percent, and 23.1 percent. The rates for the 150-mg group (P=0.02) and the 300-mg group (P=0.01) -- but not the 100-mg group (P=0.09) -- were significantly better than those for the placebo group. Among the subjects who were continuously abstinent through the end of treatment, the mean absolute weight gain was inversely associated with the dose (a gain of 2.9 kg in the placebo group, 2.3 kg in 100-mg and 150-mg groups, and 1.5 kg in the 300-mg group; P= 0.02). No effects of treatment were observed on depression scores as measured serially by the Beck Depression Inventory. Thirty-seven subjects stopped treatment prematurely because of adverse events; the frequency was similar among all groups.
CONCLUSIONS:
A sustained-release form of bupropion was effective for smoking cessation and was accompanied by reduced weight gain and minimal side effects. Many participants in all groups were smoking at one year.En ligne : https://www.nejm.org/doi/10.1056/NEJM199710233371703?url_ver=Z39.88-2003&rfr_id= [...] Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8138 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001432 TA 6.2.3.1.4 JOR E Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up Type de document : texte imprimé Auteurs : Poul Wennike, Auteur ; Tobias Danielsson, Auteur ; Björn Landfeldt, Auteur ; A. Westin, Auteur ; Philip Tonnesen, Auteur Editeur : Society for the study of addiction to alcohol and other drugs Année de publication : 2003 Collection : Addiction num. 98 Importance : p.1395-1402 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:efficacité du sevrage:motivation
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:chewing-gum
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:placeboIndex. décimale : TA 6.2.3.1.1 Chewing-gum Résumé :
Aim To test the effect of nicotine gum and placebo in smokers not motivated or not able to quit smoking with regard to smoking reduction and smoking cessation.
Design This randomized study evaluated nicotine gum versus placebo for up to 1 year in 411 healthy smokers highly motivated to reduce cigarette use. Smoking reduction was defined as self-reported daily smoking less than 50% of baseline and any decrease (1 p.p.m. or more) in carbon monoxide.
Setting Pulmonary department, Copenhagen, Denmark.
Findings The overall success rate for sustained smoking reduction was significantly higher at all time-points for active versus placebo gum (6.3% versus 0.5% after 24 months). Nicotine gum achieved significantly higher point prevalence cessation rates than placebo at 12 and 24 months [11.2% versus 3.9% (odds ratio = 3.1; 95% CI, 1.4–7.2 and 9.3% versus 3.4% (odds ratio = 2.9; 95% CI, 1.2–7.1), respectively]. There was a linear relationship between decrease in number of daily cigarettes and decrease in plasma cotinine, exhaled carbon monoxide and plasma thiocyanate, with significantly greater reduction in the nicotine gum group after 4 and 12 months (maximum treatment duration) but not after 24 months. The decrease in toxin intake was smaller than the decline in daily cigarette consumption, suggesting that compensatory smoking occurred.
Conclusions Nicotine gum promoted cessation in this population of smokers unwilling to quit. Among reducers, the toxin intake correlated with reduced cigarette consumption although some compensatory smoking occurred.
Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10327 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation Type de document : texte imprimé Auteurs : J. Taylor Hays, Auteur ; Richard D. Hurt, Auteur ; Nancy A. Rigotti, Auteur ; Raymond S. Niaura, Auteur ; David H. Gonzales, Auteur Editeur : American College of Physicians Année de publication : 2001 Collection : Annals of internal medicine, ISSN 0003-4819 num. 135 Importance : p. 423-433 Présentation : tab., graph. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] prévention
[TABAC] sevrage tabagique:efficacité du sevrage:rechute
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:placeboIndex. décimale : TA 6.2.3 Approche pharmacologique Résumé : Essai clinique randomisé ayant pour but de déterminer l'efficacité du bupropion pour prévenir la rechute. En ligne : https://doi.org/10.7326/0003-4819-135-6-200109180-00011 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10392 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline, an alpha-4-beta-2(α4β2) nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation : a randomized controlled trial Type de document : texte imprimé Auteurs : David H. Gonzales, Auteur ; Stephen I Rennard, Auteur ; Mitchell Nides, Auteur Editeur : American Medical Association (AMA) Année de publication : 01/06/2006 Collection : JAMA : Journal of the American Medical Association num. 296 (1) Importance : p.47-55 Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] étude:recherche:recherche clinique:essai clinique randomisé
[TABAC] sevrage tabagique
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:placebo
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varéniclineIndex. décimale : TA 6.2.3.1.4 Autres substituts nicotiniques En ligne : https://jamanetwork.com/journals/jama/fullarticle/211000 Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2587 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
